Follow

Swedish Indian businessman Prashant Agarwal participates in the share issue as top underwriter

23 September 2022 - 15:39

Scandinavian ChemoTech announces that Prashant Agarwal will participate as a top underwriter, with 500 000 SEK, which means he wishes to subscribe in the over-allotment option if the rights issue is fully subscribed.

Prashant has a deep understanding of the healthcare needs in emerging markets and in Europe. He brings a significant network which can benefit ChemoTech’s development. Through his holding company Ajna Holding he has interests in Sports, Food Processing and Infrastructure (Engineering, Procurement and Construction), and among them a joint-venture with Serneke International AB, where he also sits as President and CEO.  Ajna Holding's subsidiaries are also active in the trading and manufacturing of healthcare products for e.g. the NHS, UKHSC and Indian hospitals.

 

" I am very pleased to invest in Scandinavian ChemoTech, a company I believe has tremendous global opportunities and being a cancer survivor myself I am committed towards the lager cause of finding a cure or better treatment options for the world.” - says Prashant Agarwal

 

“We are very pleased to have Prashant as one of our new investors, but we are also happy to get the trust from a person with great knowledge of our industry and an enormous network in some of our core markets.” - says Mohan Frick CEO and Co-Founder of Scandinavian ChemoTech

For further information please contact: Mohan Frick, CEO

+46 (0)10-218 93 00

[email protected]

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00E-mail: [email protected]

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation (TSE™), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.

Provided by: Cision
Nasdaq First North GM Stockholm (Sweden)
Scandinavian ChemoTech AB
Scandinavian ChemoTech is a Sweden based clinical development company. It is engaged in research on pain management and therapy for prostate cancer....
Learn more about company
Media

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More